9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
39 hedge funds and large institutions have $4.4M invested in 9 Meters Biopharma in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 12 reducing their positions, and 7 closing their positions.
3,339% more call options, than puts
Call options by funds: $1.69M | Put options by funds: $49K
47% more capital invested
Capital invested by funds: $3M → $4.4M (+$1.4M)
7% less funds holding
Funds holding: 42 → 39 (-3)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
67% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.08M |
| 2 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
+$61.7K |
| 3 |
RCM
Requisite Capital Management
Dallas,
Texas
|
+$28.3K |
| 4 |
Cerity Partners
New York
|
+$20.2K |
| 5 |
Mercer Global Advisors
Denver,
Colorado
|
+$19.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$138K |
| 2 |
Renaissance Technologies
New York
|
-$111K |
| 3 |
Two Sigma Investments
New York
|
-$60K |
| 4 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
-$48.9K |
| 5 |
Millennium Management
New York
|
-$46.7K |
NMTR Hedge Fund Activity: Q1 2023 in Review
39 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q1 2023, worth a combined $4.4M — up 47% from $3M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NMTR and 6 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 4 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.08M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $138K sold.
- 39 institutional investors held 9 Meters Biopharma (NMTR) as of Q1 2023, down from 42 in Q4 2022.
- Funds reported $4.4M of 9 Meters Biopharma stock for Q1 2023, up 47% quarter-over-quarter.
- 6 funds opened new 9 Meters Biopharma positions in Q1 2023 and 7 closed out, a net change of -1 holder.
- The largest 9 Meters Biopharma buyer in Q1 2023 was Sabby Management, an estimated $2.08M added.
- The largest 9 Meters Biopharma seller in Q1 2023 was GSA Capital Partners, an estimated $138K sold.
Based on aggregated 13F filings for Q1 2023.